

--- -----  
? s glutamic acid decarboxylase

S1 1140 GLUTAMIC ACID DECARBOXYLASE  
? s s1 and antisense

1140 S1  
23939 ANTISENSE  
S2 12 S1 AND ANTISENSE  
? rd

...completed examining records  
S3 12 RD (unique items)  
? t s3/3,ab/all

3/3,AB/1 (Item 1 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

12298470 BIOSIS NO.: 200000056337  
Identification of a subpopulation of substantia nigra pars compacta  
gamma-aminobutyric acid neurons that is regulated by basal ganglia  
activity.  
AUTHOR: Hebb M O; Robertson H A(a)  
AUTHOR ADDRESS: (a)Laboratory of Molecular Neurobiology, Department of  
Pharmacology, Dalhousie University, Sir Charles Tupper Medical Building,  
Halifax, NS\*\*Canada  
JOURNAL: Journal of Comparative Neurology 416 (1):p30-44 Jan. 3, 2000  
ISSN: 0021-9967  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English

ABSTRACT: In this report, the authors provide a novel description of a  
population of gamma-aminobutyric acid-containing neurons in the  
substantia nigra, pars compacta (SNc). By using metabolic mapping of the  
immediate-early gene, c-fos, the activation pattern of these cells was  
characterized with respect to basal ganglia stimulation. Dopaminergic  
stimulation with d-amphetamine or apomorphine induced Fos expression in  
the central region of the SNc. However, lesions of the nigrostriatal  
dopamine pathway significantly reduced d-amphetamine- and  
apomorphine-induced Fos expression in the ipsilateral and contralateral  
SNc, respectively. Suppression of stimulant-induced Fos expression in the  
striatum, using **antisense** oligodeoxynucleotides, also eliminated  
Fos expression in the ipsilateral SNc, indicating that striatal efferent  
projections are involved in the activation of these cells.  
Double-labeling immunohistochemistry revealed that the Fos-positive cells  
did not express tyrosine hydroxylase but were immunoreactive for glutamic  
acid decarboxylase. Retrograde labeling of nigrostriatal neurons,  
combined with Fos immunofluorescence, revealed that these Fos-positive  
cells did not project to the striatum. Thus, these neurons do not appear  
to comprise a nondopaminergic nigrostriatal circuit but likely represent  
locally-projecting interneurons of the substantia nigra.

3/3,AB/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)

(c) 2000 BIOSIS. All rts. reserv.

12291150 BIOSIS NO.: 200000049017  
Autoimmune diabetes: Is GAD the culprit?  
AUTHOR: Lopez-Liuchi Jose V(a)  
AUTHOR ADDRESS: (a)Division d'Endocrinologie et Diabetologie, Departement  
de Medecine Interne, Hopital Universitaire de Geneve, Rue  
Micheli-du-Crest 24, 1211, Geneva 14\*\*Switzerland  
JOURNAL: European Journal of Endocrinology 141 (5):p458-459 Nov., 1999  
ISSN: 0804-4643  
DOCUMENT TYPE: Article  
RECORD TYPE: Citation  
LANGUAGE: English

3/3,AB/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

11993741 BIOSIS NO.: 199900274260  
Control of autoimmune diabetes in NOD mice by GAD expression or suppression  
in beta cells.  
AUTHOR: Yoon Ji-Won(a); Yoon Chang-Soon; Lim Hye-Won; Huang Qi Quan; Kang  
Yup; Pyun Kwang Ho; Hirasawa Kensuke; Sherwin Robert S; Jun Hee-Sook  
AUTHOR ADDRESS: (a)Laboratory of Viral and Immunopathogenesis of Diabetes,  
Julia McFarlane Diabetes Research Centre\*\*Canada  
JOURNAL: Science (Washington D C) 284 (5417):p1183-1187 May 14, 1999  
ISSN: 0036-8075  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English

ABSTRACT: Glutamic acid decarboxylase (GAD) is a pancreatic beta cell  
autoantigen in humans and nonobese diabetic (NOD) mice. beta  
Cell-specific suppression of GAD expression in two lines of  
**antisense** GAD transgenic NOD mice prevented autoimmune diabetes,  
whereas persistent GAD expression in the beta cells in the other four  
lines of **antisense** GAD transgenic NOD mice resulted in diabetes,  
similar to that seen in transgene-negative NOD mice. Complete suppression  
of beta cell GAD expression blocked the generation of diabetogenic T  
cells and protected islet grafts from autoimmune injury. Thus, beta  
cell-specific GAD expression is required for the development of  
autoimmune diabetes in NOD mice, and modulation of GAD might, therefore,  
have therapeutic value in type 1 diabetes.

3/3,AB/4 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

11966338 BIOSIS NO.: 199900219651  
An increase in glutamate release follows a decrease in gamma aminobutyric  
acid and the pubertal increase in luteinizing hormone releasing hormone  
release in female rhesus monkeys.  
AUTHOR: Terasawa E(a); Luchansky L L; Kasuya E; Nyberg C L  
AUTHOR ADDRESS: (a)Wisconsin Regional Primate Research Center, 1223 Capitol  
Court, Madison, WI, 53715-1299\*\*USA  
JOURNAL: Journal of Neuroendocrinology 11 (4):p275-282 April, 1999  
ISSN: 0953-8194  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English

ABSTRACT: Previously we have shown that release of gamma-aminobutyric acid (GABA) in the stalk-median eminence (S-ME) is high in pubertal monkeys and that a decrease in GABA release triggers the onset of puberty. However, it is still unclear how disinhibition of the luteinizing hormone releasing hormone (LHRH) neuronal system from GABA input is followed (or accompanied) by an increase in stimulatory signals, such as glutamatergic input to LHRH neurons. To clarify the temporal relationship between the reduction of the GABAergic inhibitory signal and the enhancement of the glutamatergic stimulatory signal in the control of LHRH release at the onset of puberty, we conducted two experiments using a push-pull perfusion method. In the first experiment, we measured developmental changes in release of LHRH, GABA, and glutamate in the S-ME. LHRH levels were very low in prepubertal monkeys, increased to higher levels in early pubertal monkeys, with the highest LHRH levels occurring in mid-pubertal monkeys. As we previously observed, GABA levels were high in prepubertal monkeys and then decreased in early- and mid-pubertal monkeys. In contrast, glutamate levels were very low in prepubertal monkeys, increased dramatically in early pubertal monkeys, and then slightly decreased in mid-pubertal monkeys, although mid-pubertal levels remained much higher than prepubertal levels. In the second experiment, we measured GABA, glutamate and LHRH in the same samples obtained from prepubertal monkeys which were infused with an **antisense** oligodeoxynucleotide (AS) for glutamic acid decarboxylase (GAD) 67 mRNA into the S-ME. GAD67 is a catalytic enzyme for GABA synthesis from glutamate, and AS GAD67 mRNA interferes with GAD67 synthesis. Infusion of the AS GAD67 induced a decrease in GABA release, which subsequently resulted in an increase in LHRH release. Surprisingly, glutamate release also increased several hours after the decrease in GABA release, and the increased LHRH release continued. These data are interpreted to mean that a decrease in GABA synthesis by interference with GAD67 synthesis and the reduction of GABA release in the S-ME trigger an increase in LHRH release, but that a subsequent increase in glutamate release in the S-ME further contributes to the pubertal increase in LHRH release at the onset of puberty. The data further support our hypothesis that GAD plays an important role in the mechanism of the onset of puberty.

3/3,AB/5 (Item 5 from file: 5)  
DIALOG(R)File 5: Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

11402445 BIOSIS NO.: 199800183777  
Effect of injection of **antisense** oligodeoxynucleotides of GAD isozymes into rat ventromedial hypothalamus on food intake and locomotor activity.  
AUTHOR: Bannai Makoto; Ichikawa Masumi; Nishihara Masugi; Takahashi Michio  
(a)  
AUTHOR ADDRESS: (a)Dep. Vet. Physiol., Vet. Med. Sci., Univ. Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113\*\*Japan  
JOURNAL: Brain Research 784 (1-2):p305-315 Feb. 16, 1998  
ISSN: 0006-8993  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: In the ventromedial hypothalamus (VMH), gamma-aminobutyric acid (GABA) plays a role in regulating feeding and running behaviors. The GABA synthetic enzyme, glutamic acid decarboxylase (GAD), consists of two isozymes, GAD65 and GAD67. In the present study, the phosphorothioated **antisense** oligodeoxynucleotides (ODNs) of each GAD isozyme were injected bilaterally into the VMH of male rats, and food intake, body weight and locomotor activity were monitored. ODNs were incorporated in the water-absorbent polymer (WAP, 0.2 nmol/mul) so that ODNs were retained at the injection site. Each **antisense** ODN of GAD65 or GAD67 tended to reduce food intake on day 1 (day of injection = day 0)

though not significantly. An injection combining both **antisense** ODNs significantly decreased food intake only on day 1, but body weight remained significantly lower than the control for 5 days. This suppression of body weight gain could be attributed to a significant increase in locomotor activity between days 3 and 5. Individual treatment with either ODNs did not change locomotor activity. The increase in daily locomotor activity in the group receiving the combined **antisense** ODNs occurred mainly during the light phase. Neither vehicle (WAP) nor control ODN affected food intake, body weight and locomotor activity. Histological studies indicated that **antisense** ODN distributed within 800  $\mu$ m from the edge of the area where WAP was located 24 h after the injection gradually disappeared within days, but still remained within 300  $\mu$ m distance even 7 days after the injection. **Antisense** ODN was effectively incorporated by all the cell types examined, i.e., neurons, astrocytes and microglia. Further, HPLC analysis revealed that **antisense** ODNs of GAD isozymes, either alone or combined, decreased the content of GABA by 50% in VMH 24 h after the injection. These results indicate that suppression of GABA synthesis by either of the GAD isozymes is synergistically involved in suppressing food intake and enhancing locomotor activity in rat VMH.

3/3,AB/6 (Item 6 from file: 5)  
DIALOG(R)File 5: Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

11212715 BIOSIS NO.: 199799833860  
**Antisense** oligodeoxynucleotides to two isozymes of glutamic acid decarboxylase incorporated in HVJ-liposome and injected into rat VMH differentially modify food intake.  
AUTHOR: Bannai M(a); Kaneda Y; Ichikawa M; Nishihara M; Takahashi M  
AUTHOR ADDRESS: (a)Dep. Vet. Physiol., Univ. Tokyo, Tokyo 113\*\*Japan  
JOURNAL: Society for Neuroscience Abstracts 23 (1-2):p2378 1997  
CONFERENCE/MEETING: 27th Annual Meeting of the Society for Neuroscience New Orleans, Louisiana, USA October 25-30, 1997  
ISSN: 0190-5295  
RECORD TYPE: Citation  
LANGUAGE: English

3/3,AB/7 (Item 7 from file: 5)  
DIALOG(R)File 5: Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

11208174 BIOSIS NO.: 199799829319  
Effects of infusions of **antisense** oligonucleotides for glutamic acid decarboxylase into the nucleus accumbens on behavioral vigilance.  
AUTHOR: Miner L A H; Sarter M  
AUTHOR ADDRESS: Dep. Psychol. Neurosci. Program, Ohio State Univ., Columbus, OH 43210\*\*USA  
JOURNAL: Society for Neuroscience Abstracts 23 (1-2):p1600 1997  
CONFERENCE/MEETING: 27th Annual Meeting of the Society for Neuroscience New Orleans, Louisiana, USA October 25-30, 1997  
ISSN: 0190-5295  
RECORD TYPE: Citation  
LANGUAGE: English

3/3,AB/8 (Item 8 from file: 5)  
DIALOG(R)File 5: Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

10340599 BIOSIS NO.: 199698795517  
Role of glutamic acid decarboxylase in the prepubertal inhibition of the luteinizing hormone releasing hormone release in female rhesus monkeys.

AUTHOR: Mitsushima Dai; Morzban Farshid; Luchansky Laure L; Burich Andrew J  
; Keen Kim L; Durning Green; Golos Thaddeus G; Teras Ei(a)  
AUTHOR ADDRESS: (a)Wisconsin Regional Primate Res. Cent., 1223 Capitol  
Court, Madison, WI 53715\*\*USA  
JOURNAL: Journal of Neuroscience 16 (8):p2563-2573 1996  
ISSN: 0270-6474  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: To investigate further the role of GABA in the onset of puberty, this study examines whether glutamic acid decarboxylase (GAD), the catalytic enzyme for GABA synthesis, is involved in the suppression of luteinizing hormone releasing hormone (LHRH) before puberty in rhesus monkeys. First, both GAD67 and GAD65 mRNAs were detectable by reverse transcription-PCR analysis in the preoptic area, medio-basal hypothalamus, posterior hypothalamic area, and hippocampus of the monkey brain. Second, effects of **antisense** oligodeoxynucleotides (D-oligos) for GAD67 and GAD65 mRNAs on LHRH release were examined in conscious female rhesus monkeys at the prepubertal stage using a push-pull perfusion method. The GAD67 or GAD65 **antisense** D-oligos or scrambled D-oligos were infused directly into the stalk-median eminence. Both the GAD67 and the GAD65 **antisense** D-oligos induced a large and prompt increase in LHRH release, whereas the scrambled D-oligos did not induce any significant effect. The results suggest that the removal of GABA inhibition by interfering with GAD synthesis is effective in increasing LHRH release in prepubertal monkeys. Third, the specificity of the **antisense** D-oligos on GAD levels was examined by incubating basal hypothalami with D-oligos in vitro and subsequent Western blot analysis. The **antisense** D-oligos consistently decreased the proteins GAD67 and GAD65 compared with respective control D-oligos. We conclude that the decrease of tonic GABAergic inhibition and maturational changes in GAD synthesis may be critical factors for the onset of puberty in nonhuman primates.

3/3,AB/9 (Item 9 from file: 5)  
DIALOG(R)File 5:BIOSIS Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

10074455 BIOSIS NO.: 199598529373  
**Antisense** oligonucleotide modulation of GAD alters cocaine-induced seizures in mice.  
AUTHOR: Abel M S; Kirages T J  
AUTHOR ADDRESS: Dep. Cell Biol. Anatomy, FUHS/Chicago Medical School,  
Chicago, IL 60064\*\*USA  
JOURNAL: Society for Neuroscience Abstracts 21 (1-3):p1592 1995  
CONFERENCE/MEETING: 25th Annual Meeting of the Society for Neuroscience  
San Diego, California, USA November 11-16, 1995  
ISSN: 0190-5295  
RECORD TYPE: Citation  
LANGUAGE: English

3/3,AB/10 (Item 10 from file: 5)  
DIALOG(R)File 5:BIOSIS Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

09168808 BIOSIS NO.: 199497177178  
Intracerebral administration of **antisense** oligodeoxynucleotides to GAD-65 and GAD-67 mRNAs modulate reproductive behavior in the female rat.  
AUTHOR: McCarthy Margaret M(a); Masters David B; Rimvall Karin;  
Schwartz-Giblin Susan; Pfaff Donald W  
AUTHOR ADDRESS: (a)Dep. Physiol., Univ. Md.-Sch. Med., 655 West Baltimore  
St., Baltimore, MD 20201-1559\*\*USA

JOURNAL: Brain Research 636 (2):p209-220 1994  
ISSN: 0006-8993  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

**ABSTRACT:** Increased GABA activity in the medial hypothalamus (HYP) and midbrain central gray (MCG), but not the preoptic area (POA), facilitates sexual receptivity in the female rat (40). In the current experiments, ovariectomized females were chronically treated with estrogen (via silastic capsules) to maintain a continuously high level of lordosis response. Administration of crystalline **antisense** oligodeoxynucleotide to the GABA synthetic enzyme, GAD-67, into the HYP and MCG significantly and reversibly reduced lordosis response for 1-2 days, but did not inhibit lordosis when administered into the POA. Administration of a control oligonucleotide, consisting of the same nucleotide bases but in a scrambled sequence, did not significantly modulate behavior when infused into any brain areas. When oligodeoxynucleotide **antisense** to GAD-67 was suspended in oil and then infused into the HYP or MCG it was more effective and resulted in less inter-animal variability. Subsequent experiments involving infusions into the MCG compared the effectiveness of **antisense** oligonucleotides to the two different forms of GAD, known as GAD-65 and GAD-67. Oligodeoxynucleotides **antisense** to the mRNA for either gene were effective at reducing lordosis behavior but with a different time course. Oligonucleotide **antisense** to GAD-67 significantly reduced behavior within 24 h of infusion and there was full recovery by 4 days post-infusion. GAD-65 **antisense** oligonucleotide did not significantly reduce behavior until 48 h post infusion and animals did not fully recover to pretest levels of lordosis until 5 days post-infusion. When **antisense** oligonucleotide for the two genes was administered simultaneously, the inhibition of lordosis was maximal at 24 h and stayed depressed for 4 days. There did not appear to be an additive effect of the two different **antisense** oligonucleotides when administered together. Tissue GABA levels in HYP and MCG of individual rats assayed by HPLC were no longer correlated with lordosis score after **antisense** oligonucleotide infusion but were after infusions of scrambled control oligos. Immunoblotting for the two forms of GAD revealed that GAD-67 **antisense** oligonucleotide infusion led to significant decreases in both GAD-67 and GAD-65 protein levels as compared to infusions of scrambled control oligo. In addition, the levels of a neuronal marker, neuron-specific enolase, also decreased (although nonsignificantly) suggesting either a temporary shutdown of protein synthesis or a degeneration of GABAergic neurons after GAD-67 **antisense** oligonucleotide infusion.

3/3,AB/11 (Item 11 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

09040654 BIOSIS NO.: 199497049024  
Glutamic acid decarboxylase gene expression in thalamic reticular neurons transplanted as a cell suspension in the adult thalamus.  
AUTHOR: Nothias Fatiha; Salin Pascal; Peschanski Marc; Chesselet Marie-Francoise(a)  
AUTHOR ADDRESS: (a)Dep. Pharmacol., University Pennsylvania, 36th St. and Hamilton Walk, Philadelphia, PA 19104\*\*USA  
JOURNAL: Molecular Brain Research 20 (3):p245-253 1993  
ISSN: 0169-328X  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

**ABSTRACT:** The goal of the present study was to determine whether

alterations in neuronal morphology and connections in thalamic grafts were accompanied by changes in the expression of mRNA encoding glutamic acid decarboxylase (GAD), the key enzyme in the synthesis of GABA, the normal neurotransmitter of neurons of the thalamic reticular nucleus. Cell suspensions of rat fetal tissue containing both thalamic reticular nucleus and ventrobasal primordia were transplanted into the excitotoxically lesioned somatosensory thalamus of adult rats. Levels of messenger RNA (mRNA) encoding GAD (Mr 67,000; GAD67) were measured 7 days to 4 months following transplantation via quantitative in situ hybridization with 35S-radiolabeled **antisense** RNAs. Expression of GAD67 mRNA in the thalamic reticular nucleus was analyzed in parallel in rat pups between 0 and 30 days postnatally, and in adult animals. As already observed with immunohistochemistry, transplanted neurons of the thalamic reticular nucleus did not group in specific clusters but rather mingled with unlabeled (putatively ventrobasal) neurons. Levels of labelling for GAD67 mRNA per neuron increased over time and reached adult levels during the third week post-grafting, i.e. 2 weeks after the theoretical birthdate of the neurons (grafted at embryonic days 15-16). Similar values were observed and a plateau was reached at similar time points during normal ontogeny. The results suggest that, in contrast to morphology and size of the neuronal cell bodies, gene expression of GAD67 develops normally despite the ectopic location of neurons of the thalamic reticular nucleus in the somatosensory thalamus, the abnormal connectivity and the lack of segregation from non-GABAergic neurons. Therefore, dissociation and transplantation of the tissue, resulting in disruption of the extracellular matrix and alteration of cellular interactions, differentially affects various aspects of neuronal maturation. Because neuronal activity in the graft is similar to that in the adult thalamic reticular nucleus, the results further suggest that, as shown in other experimental systems, GAD67 mRNA levels in the graft are regulated in relation to the functional activity of GABAergic neurons.

3/3,AB/12 (Item 12 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

09010907 BIOSIS NO.: 199497019277

Direct infusion of a glutamic acid decarboxylase (GAD1) **antisense** oligodeoxynucleotide into the stalk-median eminence (S-ME) increases the in vivo LHRH release in prepubertal female monkeys.

AUTHOR: Mitsushima D; Marzban F; Hei D L; Golos T G; Terasawa E

AUTHOR ADDRESS: Wis. Regional Primate Res. Cent., Univ. Wis., Madison, WI 53715\*\*USA

JOURNAL: Society for Neuroscience Abstracts 19 (1-3):p618 1993

CONFERENCE/MEETING: 23rd Annual Meeting of the Society for Neuroscience Washington, D.C., USA November 7-12, 1993

ISSN: 0190-5295

RECORD TYPE: Citation

? s glutamate and receptor and antisense

97300 GLUTAMATE  
743580 RECEPTOR  
23939 ANTISENSE  
S4 117 GLUTAMATE AND RECEPTOR AND ANTISENSE

? rd

...examined 50 records (50)  
...examined 50 records (100)  
...completed examining records  
S5 83 RD (unique items)

? s s5 and parkinson

83 S5  
46501 PARKINSON  
S6 0 S5 AND PARKINSON  
? s s5 and parkinson?

83 S5  
55750 PARKINSON?  
S7 0 S5 AND PARKINSON?  
? s s5 and nigra

83 S5  
29402 NIGRA  
S8 0 S5 AND NIGRA  
? s s5 and globus

83 S5  
8670 GLOBUS  
S9 0 S5 AND GLOBUS  
? s s5 and gaba

83 S5  
61057 GABA  
S10 6 S5 AND GABA  
? s gaba and receptor and antisense

61057 GABA  
743580 RECEPTOR  
23939 ANTISENSE  
S11 113 GABA AND RECEPTOR AND ANTISENSE  
? s s1 not s10

1140 S1  
6 S10  
S12 1140 S1 NOT S10  
? s s11 not s10

113 S11  
6 S10  
S13 107 S11 NOT S10  
? rd

...examined 50 records (50)  
...examined 50 records (100)  
...completed examining records  
S14 76 RD (unique items)



? s s14 and parkinson?

76 S14  
55750 PARKINSON?  
S15 1 S14 AND PARKINSON?  
? s s15 or s10  
1 S15  
6 S10  
S16 7 S15 OR S10  
? t s16/3,ab/all

16/3,AB/1 (Item 1 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)  
(c) format only 2000 Dialog Corporation. All rts. reserv.

10081986 99350600

Glutamatergic synaptic responses and long-term potentiation are impaired in the CA1 hippocampal area of calbindin D(28k)-deficient mice.

Jouvenneau A; Potier B; Battini R; Ferrari S; Dutar P; Billard JM

Laboratoire de Physiopharmacologie du Systeme Nerveux, Paris, France.

Synapse (UNITED STATES) Sep 1 1999, 33 (3) p172-80, ISSN 0887-4476

Journal Code: VFL

Languages: ENGLISH

Document type: JOURNAL ARTICLE

The contribution of the cytosolic calcium binding protein calbindin D(28K) (CaBP) to glutamatergic neurotransmission and synaptic plasticity was investigated in hippocampal CA1 area of wild-type and **antisense** transgenic CaBP-deficient mice, with the use of extracellular recordings in the ex vivo slice preparation. The amplitude of non-N-methyl-D-aspartate **receptor** (non-NMDAR)-mediated extracellular field excitatory postsynaptic potentials (fEPSPs) recorded in control medium was significantly greater in CaBP-deficient mice, whereas the afferent fiber volley was not affected. In contrast, the amplitude of NMDAR-mediated fEPSPs isolated in a magnesium-free medium after blockade of non-NMDAR and GABAergic receptors was significantly depressed in these animals. No alteration in the magnitude of paired-pulse facilitation was found, indicating that the presynaptic calcium mechanisms controlling **glutamate** release were not altered in CaBP-deficient mice. The magnitude and time course of the short-term potentiation (STP) of fEPSPs induced by a 30 Hz conditioning stimulation, which was blocked by the NMDAR antagonist 2-amino-5-phosphonovalerate acid (2-APV), was not impaired in the transgenic mice, whereas long-term potentiation (LTP) induced by a 100 Hz tetanus was not maintained. The long-term depression (LTD) induced by low-frequency stimulation (1 Hz, 15 min) in the presence of the **GABA** antagonist bicuculline was not altered. These results argue for a contribution of CaBP to the mechanisms responsible for the maintenance of long-term synaptic potentiation, at least in part by modulating the activation of NMDA receptors. Copyright 1999 Wiley-Liss, Inc.

16/3,AB/2 (Item 2 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)  
(c) format only 2000 Dialog Corporation. All rts. reserv.

09875101 99079264

Functional neuroanatomy of the basal ganglia as studied by dual-probe microdialysis.

O'Connor WT

Department of Human Anatomy and Physiology, University College, Dublin, Ireland. woconn@iveagh.ucd.ie

Nucl Med Biol (ENGLAND) Nov 1998, 25 (8) p743-6, ISSN 0969-8051

Journal Code: BOO

Languages: ENGLISH

Document type: JOURNAL ARTICLE

Dual probe microdialysis was employed in intact rat brain to investigate the effect of intrastriatal perfusion with selective dopamine D1 and D2 **receptor** agonists and with c-fos **antisense** oligonucleotide on (a) local **GABA** release in the striatum; (b) the internal segment of the globus pallidus and the substantia nigra pars reticulata, which is the output site of the strionigral **GABA** pathway; and (c) the external segment of the globus pallidus, which is the output site of the striopallidal **GABA** pathway. The data provide functional in vivo evidence for a selective dopamine D1 **receptor**-mediated activation of the direct strionigral **GABA** pathway and a selective dopamine D2 **receptor** inhibition of the indirect striopallidal **GABA** pathway and provides a neuronal substrate for parallel processing in the basal ganglia regulation of motor function. Taken together, these findings offer new therapeutic strategies for the treatment of dopamine-linked disorders such as **Parkinson's** disease, Huntington's disease, and schizophrenia.

16/3,AB/3 (Item 3 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2000 Dialog Corporation. All rts. reserv.

09841607 99124487

A role of gamma-amino butyric acid (**GABA**) and **glutamate** in control of puberty in female rhesus monkeys: effect of an **antisense** oligodeoxynucleotide for GAD67 messenger ribonucleic acid and MK801 on luteinizing hormone-releasing hormone release.

Kasuya E; Nyberg CL; Mogi K; Terasawa E  
Wisconsin Regional Primate Research Center, University of Wisconsin-Madison, 53715-1299, USA.  
Endocrinology (UNITED STATES) Feb 1999, 140 (2) p705-12, ISSN 0013-7227 Journal Code: EGZ  
Contract/Grant No.: HD-11355, HD, NICHD; HD-15433, HD, NICHD; RR-00167, RR, NCRR

Languages: ENGLISH

Document type: JOURNAL ARTICLE

Previously we have shown that gamma-aminobutyric acid (**GABA**) is an inhibitory neurotransmitter restricting the pubertal increase in LHRH release in juvenile monkeys, and that interfering with **GABA** synthesis with an **antisense** oligodeoxynucleotide (AS) for glutamic acid decarboxylase (GAD67) mRNA results in an increase in LHRH release in prepubertal monkeys. GAD67 is a catalytic enzyme that synthesizes **GABA** from **glutamate**. To further clarify the role of **GABA** in puberty, we examined whether the inhibition of LHRH release by **GABA** continues after the onset of puberty and whether input from glutamatergic neurons plays any role in the onset of puberty when **GABA** inhibition declines, using a push-pull perfusion method. In Study I, the effects of the AS GAD67 mRNA on LHRH release in pubertal monkeys (34.3 +/- 1.5 months of age, n = 8) were examined, and the results were compared with those in prepubertal monkeys (18.5 +/- 0.4 months, n = 12). Direct infusion of AS GAD67 (1 microm) into the stalk-median eminence (S-ME) for 5 h stimulated LHRH release in both prepubertal and pubertal monkeys. However, the increase in LHRH release in pubertal monkeys was significantly (P < 0.01) smaller than that in prepubertal monkeys. Infusion of a scrambled oligo as a control was without effect in either group. In Study II, to examine the possibility that an increase in **glutamate** tone after the reduction of an inhibitory **GABA** tone contributes to the AS GAD67-induced LHRH increase, the effects of the NMDA **receptor** blocker MK801 (5 microm) on LHRH release were tested in monkeys treated with AS GAD67. MK801 infusion into the S-ME during the treatment of AS GAD67 (1 microm) suppressed the AS GAD67-induced LHRH release in both age groups. MK801 alone did not cause any significant effect in either group. The data are interpreted to mean that **GABA** continues to suppress LHRH release after the onset of puberty, although the degree of suppression is weakened considerably after the onset of puberty, and that the increased

LHRH release after AS GAD67 treatment may be partly due to an increase in **glutamate** tone mediated by NMDA receptors, as well due to the decrease in **GABA** release following the decrease in GAD synthesis. Taken together, the present results suggest that GAD may play an important role in the onset and progress of puberty in nonhuman primates.

16/3,AB/4 (Item 4 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)  
(c) format only 2000 Dialog Corporation. All rts. reserv.

08898046 96233196

Cocaine selectively alters neurotransmitter **receptor** mRNAs in mouse embryos.

Mackler SA; Bennett GD; Tsuei VP; Finnell RH  
Division of General Internal Medicine, University of Pennsylvania, Philadelphia, USA.

Reprod Toxicol (UNITED STATES) Jan-Feb 1996, 10 (1) p37-42, ISSN 0890-6238 Journal Code: BE4

Contract/Grant No.: ES07165, ES, NIEHS; DE11303, DE, NIDR; DA00199, DA, NIDA

Languages: ENGLISH

Document type: JOURNAL ARTICLE

Alterations in gene expression due to in utero cocaine exposure may adversely affect nervous system development. The present study examined whether or not cocaine administration to pregnant mice alters embryonic mRNA levels for several developmentally-regulated genes. **Antisense** RNA amplification was performed using RNA from LM/Bc embryos at gestational days 9.5 and 10.5 after three days of cocaine treatment. This technique highlights simultaneous changes that occur in the expression of many genes after a teratogenic insult. Significant changes occurred in the expression pattern on only four genes from a total of 42 candidate cDNAs. These included increases in the relative levels of the alpha and beta 1 subunits of the **GABAA receptor** without concurrent changes in the non-NMDA **glutamate receptor** subunits. The results support the hypothesis that in utero cocaine exposure leads to specific changes in gene expression that may ultimately contribute to developmental abnormalities.

16/3,AB/5 (Item 5 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)  
(c) format only 2000 Dialog Corporation. All rts. reserv.

08400577 95388262

**Antisense** oligonucleotide-induced block of individual **GABAA receptor** alpha subunits in cultured visual cortex slices reduces amplitude of evoked inhibitory postsynaptic currents.

Brussaard AB; Baker RE  
Graduate School Neurosciences Amsterdam, Research Institute Neurosciences, Vrije Universiteit, Faculty of Biology, The Netherlands.

Neurosci Lett (IRELAND) May 19 1995, 191 (1-2) p111-5, ISSN 0304-3940  
Journal Code: N7N

Languages: ENGLISH

Document type: JOURNAL ARTICLE

Whole cell patch clamp recordings were made in layer II-IV from organotypic slices of rat primary visual cortex, explanted at postnatal day 6 and maintained in a serum-free medium. Neurons evinced current clamp characteristics typical for stellate cells. Between 7 and 21 days in culture, both **glutamate**- and **GABA**-mediated postsynaptic currents were observed. Long-term culturing in the presence of a degenerate 15-mer **antisense** oligonucleotide directed against the transcripts of all alpha subunits genes of the **GABAA receptor** resulted in a dose dependent reduction of evoked **GABA** synaptic currents. This reduction was maximal (80%) at 20 microM. A randomized control oligo had no effect. Evoked glutamatergic excitatory postsynaptic currents were unaffected

following oligo treatment. A 15-mer **antisense** oligo directed against the alpha 1 subunit gave variable effects: in some cells the amplitude of evoked GABAergic inhibitory postsynaptic currents (IPSCs) was reduced by 50-75%, while in other cells recorded from the same slices, there was little or no effect. An **antisense** oligo, directed against the alpha 2 subunit, however, gave a consistent and robust 80% reduction of the amplitude of evoked IPSCs. A 15-mer 3-base mismatch oligo against alpha 2 had no effect. We conclude that the alpha 2 subunit functions in postsynaptic GABAA receptors located on or close to the cell bodies of stellate cells. The role of the alpha 1 subunit is less clear, but this subunit seems spatially differentiated. The in situ **antisense** oligo technique should provide further insight into the biophysical and pharmacological consequences of the subunit composition of ligand gated channels at functional synapses.

16/3,AB/6 (Item 6 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)  
(c) format only 2000 Dialog Corporation. All rts. reserv.

07293308 93148187  
Building a bridge between neurobiology and mental illness.  
Costa E  
Fidia-Georgetown Institute for the Neurosciences, Georgetown University Medical School, Washington, DC 20007.  
J Psychiatr Res (ENGLAND) Oct 1992, 26 (4) p449-60, ISSN 0022-3956  
Journal Code: JTJ  
Languages: ENGLISH  
Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL  
**GABA** (gamma amino butyric acid) is the most abundant and important inhibitory transmitter in mammalian CNS. It counterbalances the **glutamate** mediated neuronal excitation. Abnormalities of the interaction of these two transmitters might change the mechanisms of neuronal group selection that according to Edelman [Neural Darwinism. Basic Books, New York] play a role in mediating several brain functions including cognition processes. Indeed imbalances in GABAergic functions were shown to elicit psychoses. They can be obtained by administration of drugs that affect synthesis, metabolism and uptake of **GABA** and thereby cause a persistent stimulation of GABAA receptors or perhaps by genetic abnormalities in DNA transcription, pre-mRNA splicing, mRNA translation and posttranslation modifications of GABAA **receptor** subunits. The complexities in the regulation of GABAA **receptor** subunit structure, synthesis, assembly and the brain location of specific mRNA encoding for these subunits are investigated with in situ mRNA hybridization specific for subunits of GABAA receptors. The role of the variability resulting from the complexities in the regulation of GABAA **receptor** allosteric modulation by drugs and putative endogenous allosteric modulators of **GABA** action at GABAA receptors is discussed. This discussion gives relevance to the possibility that genetic abnormalities in the expression of proteins participating in GABAergic function are to be considered as a possible target of the genetic defects operative in psychoses. In line with this thinking, it is suggested that partial allosteric modulators (partial agonists) of GABAA receptors and the phosphothioate or methylphosphonate analogs **antisense** to specific mRNA oligonucleotides that mediate the expression of genetic information concerning GABAA and **glutamate receptor** subunits may become valuable tools in psychiatric research. Perhaps in the future these studies might generate new ideas useful in the therapy of genetically determined psychiatric illness.

16/3,AB/7 (Item 7 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)  
(c) format only 2000 Dialog Corporation. All rts. reserv.

06953708 92076443

Cellular distribution of L-glutamate decarboxylase (GAD) and gamma-aminobutyric acid (GABA) receptor mRNAs in the retina.

Brecha NC; Sternini C; Humphrey MF

Department of Medicine, UCLA 90024.

Cell Mol Neurobiol (UNITED STATES) Oct 1991, 11 (5) p497-509, ISSN 0272-4340 Journal Code: CPX

Contract/Grant No.: EY 04067, EY, NEI; DK 38752, DK, NIDDK; DK 40469, DK, NIDDK

Languages: ENGLISH

Document type: JOURNAL ARTICLE

1. Gamma-aminobutyric acid (GABA), a major inhibitory transmitter of the vertebrate retina, is synthesized from glutamate by L-glutamate decarboxylase (GAD) and mediates neuronal inhibition at GABA receptors. GAD consists of two distinct molecular forms, GAD65 and GAD67, which have similar distribution patterns in the nervous system (Feldblum et al., 1990; Erlander and Tobin, 1991). GABA receptors are composed of several distinct polypeptide subunits, of which the GABA alpha 1 variant has a particularly extensive and widespread distribution in the nervous system. The aim of this study was to determine the cellular localization patterns of GAD and GABA alpha 1 receptor mRNAs to define GABA- and GABA receptor-synthesizing neurons in the rat retina. 2. GAD and GABA alpha 1 mRNAs were localized in retinal neurons by in situ hybridization histochemistry with 35S-labeled antisense RNA probes complementary to GAD67 and GABA alpha 1 mRNAs. 3. The majority of neurons expressing GAD67 mRNA is located in the proximal inner nuclear layer (INL) and ganglion cell layer (GCL). Occasional GAD67 mRNA-containing neurons are present in the inner plexiform layer. Labeled neurons are not found in the distal INL or in the outer nuclear layer (ONL). 4. GABA alpha 1 mRNA is expressed by neurons distributed to all regions of the INL. Some discretely labeled cells are present in the GCL. Labeled cells are not observed in the ONL. 5. The distribution of GAD67 mRNA demonstrates that numerous amacrine cells (conventional, interstitial, and displaced) and perhaps interplexiform cells synthesize GABA. These cells are likely to employ GABA as a neurotransmitter. 6. The distribution of GABA alpha 1 mRNA indicates that bipolar, amacrine, and perhaps ganglion cells express GABA receptors having an alpha 1 polypeptide subunit, suggesting

```

150 S9
286 S10
S11 23 S9 AND S10
? rd
...completed examining records
S12 15 RD (unique items)
? s s12 not s5
15 S12
6 S5
S13 15 S12 NOT S5
? t s13/3,ab/all

13/3,AB/1 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

```

09858743 98292485 PMID: 9628768

Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned **rat model of Parkinson's disease**.

Henry B; Crossman A R; Brotchie J M  
 Division of Neuroscience, School of Biological Sciences, University of Manchester, 1.124 Stopford Building, Manchester, M13 9PT, United Kingdom.  
 Experimental<sup>tt</sup> neurology (UNITED STATES) Jun 1998, 151 (2)  
 p334-42, ISSN 0014-4886 Journal Code: 0370712  
 Document type: Journal Article  
 Languages: ENGLISH  
 Main Citation Owner: NLM  
 Record type: Completed

Long-term treatment of **Parkinson's disease** with dopamine-replacing agents such as L-3,4-dihydroxyphenylalanine (L-DOPA) is compromised by many side-effects, most notably involuntary movements, L-DOPA-induced dyskinesia. Acute challenge with dopamine-replacing drugs elicits a rotational response in the 6-hydroxydopamine (6-OHDA)-lesioned **rat model of Parkinson's disease**. This rotation is contraversive to the lesion and is considered to represent an antiparkinsonian effect. More recently, it has become clear that the rotational response shows plasticity and that repeated L-DOPA or apomorphine therapy is accompanied by a marked enhancement in this response. In this study, we demonstrate that the enhanced behavioral response to repeated dopamine-replacement therapy seen in the 6-OHDA-lesioned **rat** has pharmacological characteristics similar to L-DOPA-induced dyskinesia seen in **MPTP**-lesioned primates and man.

Thus, the magnitude and rate of development of the enhanced response to L-DOPA treatment is related to both the number of doses and the size of the dose of L-DOPA administered. In contrast, de novo administration of dopaminergic drugs that are associated with a lower incidence of dyskinesia, e.g., bromocriptine or lisuride, does not lead to an enhanced behavioral response following repeated treatment. However, following a single "priming" administration of apomorphine, the rotational response elicited by subsequent bromocriptine administrations is enhanced with repeated treatment. Once established, the enhanced behavioral response to repeated L-DOPA-administration (6.5 mg/kg, twice daily) can, like L-DOPA-induced dyskinesia in man and **MPTP**-treated monkeys, be selectively reduced by coadministration of L-DOPA with the alpha2-adrenergic receptor antagonist yohimbine (10 mg/kg, -95%), the 5-HT uptake inhibitor 5-MDOT (2 mg/kg, -90%), or the beta-adrenergic receptor antagonist propranolol (10 mg/kg, -35%). While these rats do not exhibit symptoms of dyskinesia per se, this **rodent model** does exhibit behaviors, the underlying mechanism of which is likely to be similar to that underlying L-DOPA-induced dyskinesia and may prove useful in studying the molecular and cellular mechanisms of L-DOPA-induced dyskinesia in **Parkinson's disease**. Copyright 1998 Academic Press.

13/3,AB/2 (Item 2 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)

09102111 97022910 PMID: 8869270

Experimental **models** and behavioural tests used in the study of **Parkinson's** disease.

Mokry J

Department of Histology and Embryology, Charles University Medical School, Hradec Kralove, Czech Republic.

Physiological research / Academia Scientiarum Bohemoslovaca ( CZECH REPUBLIC) 1995, 44 (3) p143-50, ISSN 0862-8408 Journal Code: 9112413

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

The present review brings the survey of the most frequently used behavioural tests in experimental **models** of **Parkinson's** disease (PD). Although there is no spontaneous occurrence of **parkinsonism** in **animals**, several experimental **animal models** of PD have been developed to achieve the same clinical features in **animals**. The techniques employing neurotoxins in lesioning the nigrostriatal dopaminergic (DA) system have a large selectivity and reproducibility. The most frequently used neurotoxins are 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (**MPTP**) and 6-hydroxydopamine (**6-OHDA**). **MPTP**-lesioned monkeys mimic best the symptomatology of PD in human patients while rats appear to be refractory to **MPTP**. For that reason, **6-OHDA** is used to damage the substantia nigra in a **rodent model**. Behavioural tests of **animals** with nigrostriatal lesion represent valuable non-invasive methods for assessing the influence of damaged DA system on locomotor activity. The most frequently used experimental **model** of PD is the drug-evoked rotation in **6-OHDA** unilaterally lesioned rats. This **model** produces well-defined and stable behavioural deficits. The rotation test is a useful parameter for evaluating imbalances of dopamine in both striata of the hemi-**parkinsonian rat model**. T-maze, treadmill running test or sensorimotor tests are used to evaluate spontaneous locomotor activity of lesioned **animals**. Skilled motor tasks measure the influence of dopamine-depleting lesions on complex motor acts. Transplantation of DA tissue into the striatum offers a new approach to the treatment of PD. Experimental **models** and behavioural tests are used to evaluate the extent of graft-induced recovery of **MPTP**- or **6-OHDA**-lesioned **animals**. Different results obtained after the use of different tests reflect the level of graft integration into the host circuitry.

13/3,AB/3 (Item 3 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)

08972152 96325519 PMID: 8714707

Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the **rodent** and **primate** striatum.

Doucet J P; Nakabeppu Y; Bedard P J; Hope B T; Nestler E J; Jasmin B J; Chen J S; Iadarola M J; St-Jean M; Wigle N; Blanchet P; Grondin R; Robertson G S

Department of Pharmacology, University of Ottawa, Ottawa, Ontario, Canada K1H 8M5.

European journal of neuroscience (ENGLAND) Feb 1996, 8 (2) p365-81, ISSN 0953-816X Journal Code: 8918110

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Using an antibody that recognizes the products of all known members of the fos family of immediate early genes, it was demonstrated that destruction of the nigrostriatal pathway by 6-hydroxydopamine (6-OHDA) lesions of the medial forebrain bundle produces a prolonged (>3 months) elevation of Fos-like immunoreactivity in the striatum. Using retrograde tract tracing techniques, we have previously shown that this increase in Fos-like immunoreactivity is located predominantly in striatal neurons that project to the globus pallidus. In the present study, Western blots were performed on nuclear extracts from the intact and denervated striatum of 6-OHDA-lesioned rats to determine the nature of Fos-immunoreactive protein(s) responsible for this increase. Approximately 6 weeks after the 6-OHDA lesion, expression of two Fos-related antigens with apparent molecular masses of 43 and 45 kDa was enhanced in the denervated striatum. Chronic haloperidol administration also selectively elevated expression of these Fos-related antigens, suggesting that their induction after dopaminergic denervation is mediated by reduced activation of D2-like dopamine receptors. Western blot immunostaining using an antibody which recognizes the N-terminus of FosB indicated that the 43 and 45 kDa Fos-related antigens induced by dopaminergic denervation and chronic haloperidol administration may be related to a truncated form of FosB known as deltaFosB. Consistent with this proposal, retrograde tracing experiments confirmed that deltaFosB-like immunoreactivity in the deafferented striatum was located predominantly in striatopallidal neurons. Gel shift experiments demonstrated that elevated AP-1 binding activity in denervated striata contained FosB-like protein(s), suggesting that enhanced deltaFosB levels may mediate some of the effects of prolonged dopamine depletion on AP-1-regulated genes in striatopallidal neurons. In contrast, chronic administration of the D1-like receptor agonist CY 208243 to 6-OHDA-lesioned rats dramatically enhanced deltaFosB-like immunoreactivity in striatal neurons projecting to the substantia nigra. Western blot immunostaining revealed that deltaFosB and, to a lesser extent, FosB are elevated by chronic D1-like agonist administration. Both the quantitative reverse transcriptase-polymerase chain reaction and the ribonuclease protection assay demonstrated that deltafosB mRNA levels were substantially enhanced in the denervated striatum by chronic D1-like agonist administration. Lastly, we examined the effects of chronic administration of D1-like and D2-like dopamine receptor agonists on striatal deltaFosB expression in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate model of Parkinson's disease. In monkeys rendered Parkinsonian by MPTP, there was a modest increase in deltaFosB-like protein(s), while the development of dyskinesia produced by chronic D1-like agonist administration was accompanied by large increases in DeltaFosB-like protein(s). In contrast, administration of the long-acting D2-like agonist cabergoline, which alleviated Parkinsonian symptoms without producing dyskinesia reduced deltaFosB levels to near normal. Taken together, these results demonstrate that chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum.

13/3,AB/4 (Item 4 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)

08734239 96085946 PMID: 8527000

The expression of proenkephalin and prodynorphin genes and the induction of c-fos gene by dopaminergic drugs are not altered in the striatum of MPTP-treated mice.

Ziolkowska B; Horn G; Kupsch A; Holtt V

Neuropeptide Research Department, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland.

Journal of neural transmission. Parkinson's disease and dementia section (AUSTRIA) 1995, 9 (2-3) p151-64, ISSN 0936-3076



Journal Code: 8914371

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

The expression of proenkephalin (PENK), prodynorphin (PDYN) and c-fos genes was studied in the striatum of C57B1/6 mice treated with 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP), which are used as a rodent model of Parkinson's disease (PD). Two weeks after systemic administration of MPTP (2 x 40 mg/kg, s.c. 18h apart), the lesion of the substantia nigra (SN) could be visualised by loss of the nigral tyrosine hydroxylase (TH) mRNA hybridization signal and by a 91% decrease in striatal dopamine levels. The levels of PENK and PDYN mRNAs were not significantly changed in the striatum of the lesioned mice, as compared to non-treated controls. The induction of the immediate early gene c-fos by the dopamine D2 receptor antagonist haloperidol was not altered, while the selective D1 receptor agonist SKF 38393 failed to induce c-fos in the striatum of MPTP-treated mice. These results are in contrast to the data concerning rats with the 6-hydroxydopamine (6-OHDA) lesion of the SN, which serve as another rodent model of PD. In the striata of 6-OHDA-lesioned rats, PENK gene is upregulated, PDYN gene is down-regulated and the induction of c-fos gene by D2 receptor antagonists is abolished, whereas selective D1 receptor agonists induce c-fos gene, which does not occur in non-lesioned rats. We presume that the lack of influence of the MPTP lesion in mice on the striatal gene expression was mainly caused by insufficient dopamine depletion in the striatum, which could not be increased in this model. The importance of the changes observed in 6-OHDA-lesioned rats has been discussed in the context of the mouse and primate MPTP models of PD.

13/3,AB/5 (Item 5 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)

08699014 96033746 PMID: 7472415

In a rat model of parkinsonism, lesions of the subthalamic nucleus reverse increases of reaction time but induce a dramatic premature responding deficit.

Baunez C; Nieoullon A; Amalric M  
Laboratoire de Neurobiologie Cellulaire et Fonctionnelle, CNRS, Marseille, France.

Journal of neuroscience : the official journal of the Society for Neuroscience (UNITED STATES) Oct 1995, 15 (10) p6531-41, ISSN 0270-6474 Journal Code: 8102140

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Lesions of the subthalamic nucleus (STN) have been found to reduce the severe akinetic motor symptom produced in animal models of Parkinson's disease, such as in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or in monoamine-depleted rats. However, little is known about the effect of STN excision on subtle motor deficits induced by moderate dopaminergic lesions in complex motor tasks. The present study was thus performed on rats trained in a reaction time (RT) task known to be extremely sensitive to variations of dopamine transmission in the striatum. Animals were trained to release a lever after the onset of a visual stimulus within a time limit to obtain a food reward. Discrete dopamine depletion produced by infusing the neurotoxin 6-hydroxydopamine (6-OHDA) bilaterally into the dorsal part of the striatum, produced motor initiation deficits which were revealed by an increase in the number of delayed responses (lever release after the time limit) and a lengthening of RTs. In contrast,

bilateral excitotoxic lesion of the STN with ibotenic acid induced severe behavioral deficits which were opposite to those produced by the dopaminergic lesion, as shown by an increase in the number of premature responses (lever release before the onset of the visual stimulus) and a decrease of RTs. Surprisingly, the performance of the animals bearing a double lesion (striatal dopaminergic lesion followed 14 d later by STN ibotenic lesion) was still impaired 40 d after the ibotenic lesion. As expected, the 6-OHDA-induced motor initiation deficits were reversed by a subsequent STN lesion. However, the dramatic increase of premature responses contributing to major behavioral deficits induced by the STN lesion remained unchanged. Thus, the bilateral lesion of the STN was found to alleviate the motor deficits in this model of parkinsonism, but essentially produced over time, long lasting deficits that might be related to dyskinesia or cognitive impairment. The present results strongly support the recent concept of a predominant control of the STN on basal ganglia output structures.

13/3,AB/6 (Item 6 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)

08569380 95327796 PMID: 7604140

Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate.

Gnanalingham K K; Hunter A J; Jenner P; Marsden C D  
Parkinson's Disease Society Experimental Research Laboratories, King's College, London, UK.

Psychopharmacology (GERMANY) Feb 1995, 117 (4) p403-12, ISSN 0033-3158 Journal Code: 7608025

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

In rats with unilateral 6-hydroxydopamine (6-OHDA) lesions of the medial forebrain bundle, pretreatment with the D1 DA antagonists, SCH 23390 (7-chloro-8-hydroxy-2,3,4,5-tetrahydro-3-methyl-1-phenyl-1H-3-benzazepine) and A66359 (1-(2-bromo-4,5-dimethoxybenzyl)-7-hydroxy-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline), but not the D2 DA antagonist raclopride inhibited the contralateral circling induced by the benzazepine D1 DA agonists SKF 38393 (7-H, 3-H analogue of SCH 23390), SKF 80723 (7-H, 3-H, 6-Br analogue) and SKF 83959 (7-H, 6-Cl, 3'-CH<sub>3</sub> analogue). In MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) treated common marmosets, administration of SKF 80723 and SKF 83959 increased locomotor activity and reversed the motor disability. Grooming and oral activities were also increased. Pretreatment with SCH 23390 and A66359 inhibited all the behavioural changes induced by both D1 DA agonists. In general, higher doses of A66359 and more especially SCH 23390 were needed to inhibit SKF 83959 and SKF 80723 induced increases in oral activity and grooming than locomotor activity. Raclopride pretreatment did not affect SKF 83959 and SKF 80723 induced oral activity and grooming, though it reduced the duration of the locomotor changes induced by the D1 DA agonists. These findings demonstrate that the behavioural effects of benzazepine D1 DA agonists in the 6-OHDA lesioned rat and MPTP-treated marmoset are mediated by D1 DA receptor sites, although in the primate, stimulation of D2 DA receptors by endogenous DA may be necessary in facilitating the antiparkinsonian effects of D1 DA agonists. The differential sensitivities of locomotor/motor disability and oral/grooming behaviours to antagonism by D1 DA antagonists may indicate the involvement of multiple D1 DA receptor subtypes in mediating benzazepine D1 DA agonist induced behaviours in the MPTP-treated marmoset.

13/3,AB/7 (Item 7 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)

08531765 95288444 PMID: 7770604

The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in **primate** and **rodent models** of **Parkinson's disease**.

Gnanalingham K K; Hunter A J; Jenner P; Marsden C D

Parkinson's Disease Society, Experimental Research Laboratories, King's College, London, U.K.

Psychopharmacology (GERMANY) Feb 1995, 117 (3) p287-97, ISSN 0033-3158 Journal Code: 7608025

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

The effects of co-administration of quinpirole with benzazepine D1 dopamine (DA) agonists possessing full/supramaximal (SKF 80723 and SKF 82958), partial (SKF 38393 and SKF 75670) and no efficacies (SKF 83959) in stimulating adenylate cyclase (AC) were investigated in **rodent** and **primate models** of **Parkinson's disease** (PD). In rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion of the medial forebrain bundle, co-administration of SKF 38393 (7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine), SKF 75670 (3-CH<sub>3</sub> analogue), SKF 80723 (6-Br analogue), SKF 83959 (6-Cl, 3-CH<sub>3</sub>, 3'-CH<sub>3</sub> analogue) and SKF 82958 (6-Cl, 3-C<sub>3</sub>H<sub>5</sub> analogue) strongly potentiated the contralateral circling induced by quinpirole. In **MPTP** (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) treated common marmosets, administration of quinpirole alone increased locomotor activity and reversed motor deficits. Grooming and oral activity were unaltered. Co-administration of SKF 38393 and SKF 75670 inhibited the quinpirole-induced changes in locomotor activity and motor disability. The combined treatment of SKF 80723 or SKF 82958 with quinpirole had no overall effect on locomotor activity or motor disability. In contrast, SKF 83959 extended the duration of the quinpirole-induced increase in locomotor activity with corresponding decreases in motor disability. Co-administration of high doses of SKF 82958 and more especially SKF 83959 and SKF 80723, with quinpirole induced hyperexcitability and seizures. Oral activity and grooming were unaltered following the co-administration of benzazepine derivatives with quinpirole. The ability of some benzazepine D1 DA agonists to prolong the antiparkinsonian effects of quinpirole in the **MPTP**-treated marmoset may indicate a role for certain D1 DA agonists in the clinical treatment of PD. In general, the behavioural responses to the combined administration of benzazepines with quinpirole in the 6-OHDA lesioned rat and more especially the **MPTP**-treated marmoset failed to correlate with their ability to stimulate AC. These observations further implicate a behavioural role for D1 DA receptors not linked to AC.

13/3,AB/8 (Item 8 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)

07622110 93147822 PMID: 1491248

Synergism of NBQX with dopamine agonists in the 6-OHDA rat model of **Parkinson's disease**.

Loschmann P A; Kunow M; Wachtel H

Research Laboratories, Schering AG, Berlin, Federal Republic of Germany.

Journal of neural transmission. Supplementum (AUSTRIA) 1992, 38 p55-64, ISSN 0303-6995 Journal Code: 0425126

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Advance in understanding of the anatomy, physiology and pharmacology of basal ganglia organisation over the past decade revealed a functional relation between excitatory glutamatergic and the degenerated dopaminergic nigrostriatal transmitter systems which could serve as targets for pharmacological interventions in **Parkinson's** disease. The selective AMPA-antagonist NBQX is not effective in **animal models** of **Parkinson's** disease when given alone but ameliorates **parkinsonian** symptomatology and enhances the locomotor response of a threshold dose of L-DOPA. These synergistic effects are seen in the **MPTP** -treated (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) common marmoset and the **rat** with unilateral 6-hydroxydopamine (6-OHDA) lesions of the substantia nigra. Here we report that, in the latter **model**, such synergism of NBQX is also seen with the direct dopamine agonists lisuride and apomorphine, indicating the potential usefulness of AMPA antagonists for the symptomatic treatment of **Parkinson's** disease.

13/3,AB/9 (Item 9 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)

07619766 93125584 PMID: 8419792

The possible role of iron in the etiopathology of **Parkinson's** disease.

Youdim M B; Ben-Shachar D; Riederer P  
Department of Pharmacology, Bruce Rappaport Faculty of Medicine,  
Technion, Haifa, Israel.

Movement disorders : official journal of the Movement Disorder Society ( UNITED STATES) 1993, 8 (1) p1-12, ISSN 0885-3185

Journal Code: 8610688

Erratum in Mov Disord 1993 Apr;8(2) 255

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

The identification of 6-hydroxydopamine (6-OHDA) and N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (**MPTP**) as dopaminergic neurotoxins that can induce **parkinsonism** in humans and **animals** has contributed to a better understanding of **Parkinson's** disease (PD). Although the involvement of similar neurotoxins has been implicated in PD, the etiology of the disease remains obscure. However, the recently described pathology of PD supports the view for a state of oxidative stress in the substantia nigra (SN), resulting as a consequence of the selective accumulation of iron in SN zona compacta and within the melanized dopamine neurons. Whether iron is directly involved cannot be ascertained. Nevertheless, the biochemical changes due to oxidative stress resulting from tissue iron overload (siderosis) are similar to those now being identified in **parkinsonian** SN. These include the reduction of mitochondrial electron transport, complex I and III activities, glutathione peroxidase activity, glutathione (GSH) ascorbate, calcium-binding protein, and superoxide dismutase and increase of basal lipid peroxidation and deposition of iron. The participation of iron-induced oxygen free radicals in the process of nigrostriatal dopamine neuron degeneration is strengthened by recent studies in which the neurotoxicity of 6-OHDA has been linked to the release of iron from its binding sites in ferritin. This is further supported by experiments with the prototype iron chelator, desferrioxamine (Desferal), a free-radical inhibitor, which protects against 6-OHDA-induced lesions in the **rat**. Indeed, intranigral iron injection in rats produces a selective lesioning of dopamine neurons, resulting in a behavioral and biochemical **parkinsonism**.

13/3,AB/10 (Item 10 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

07562204 93086829 PMID: 1280793

NBQX (6-nitro-sulfamoyl-benzo-quinoxaline-dione) and CPP (3-carboxy-piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats.

Wachtel H; Kunow M; Loschmann P A

Research Laboratories of Schering AG, Berlin, FRG.

Neuroscience letters (NETHERLANDS) Aug 17 1992, 142 (2)

p179-82, ISSN 0304-3940 Journal Code: 7600130

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Degeneration of dopaminergic nigrostriatal neurons in **primate models** of **Parkinson's** disease (PD) leads to an overactivity of excitatory glutamatergic projections from the subthalamic nucleus (STN) to the output nuclei of the basal ganglia resulting in rigidity and akinesia. The selective alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) antagonist 6-nitro-sulfamoyl-benzo-quinoxaline-dione (NBQX) and the competitive N-methyl-D-aspartate (NMDA) antagonist 3-carboxy-piperazin-propyl phosphonic acid (CPP) ameliorate **parkinsonian** symptomatology when co-administered with threshold doses of L-DOPA in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (**MPTP**)-treated common marmosets and induce rotations in rats with unilateral 6-hydroxydopamine (6-OHDA) lesions of the substantia nigra (SN). Here we report that in the 6-OHDA-lesioned rat NBQX and CPP induce contralateral rotations when combined with threshold doses of the direct dopamine agonists lisuride or apomorphine. AMPA antagonists and competitive NMDA antagonists may therefore be suitable as adjuvants for the treatment of PD.

13/3,AB/11 (Item 11 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

06289139 89376009 PMID: 2528389

A 6-hydroxydopamine-induced selective **parkinsonian rat model**.

Perese D A; Ulman J; Viola J; Ewing S E; Bankiewicz K S

Surgical Neurology Branch, NINCDS, Bethesda, MD 20892.

Brain research (NETHERLANDS) Aug 14 1989, 494 (2) p285-93,

ISSN 0006-8993 Journal Code: 0045503

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Previous **parkinsonian rat models** have generally been characterized by unilateral destruction of both the nigrostriatal pathway and the mesolimbic pathway using the neurotoxin 6-hydroxydopamine (6-OHDA). We created a hemiparkinsonian **model** in which there is 6-OHDA-induced destruction of the dopaminergic nigrostriatal pathway but sparing of the dopaminergic mesolimbic pathway. This resulted in reproducible, quantifiable rotational behavior in response to either amphetamine or apomorphine and a near total depletion of dopamine in the striatum ipsilateral to the lesion with a dorsolateral distribution of supersensitive dopaminergic D2 receptors. This **model** parallels the **MPTP** (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced hemiparkinsonian **model** in primates and more closely approximates the extent of neurodegeneration seen in human idiopathic **Parkinson's** disease than previous **parkinsonian rat models**. It may therefore prove a convenient **model** for studying the recently reported phenomenon of sprouting from host dopaminergic neurons following tissue implantation.

13/3,AB/12 (Item 12 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)

05858722 88281296 PMID: 3134931

Transplantation of the superior cervical ganglion into the brain--a new experimental therapy of **Parkinson** disease]

Itakura T; Kamei I; Nakai K; Nakai M; Naka Y; Nakakita K; Imai H; Komai N  
Department of Neurological Surgery Wakayama Medical College, Japan.

No to shinkei. Brain and nerve (JAPAN) Mar 1988, 40 (3)

p285-90, ISSN 0006-8969 Journal Code: 0413550

Document type: Journal Article ; English Abstract

Languages: JAPANESE

Main Citation Owner: NLM

Record type: Completed

To supplement catecholamine deficit in the brain with **Parkinson** disease, we have aimed to transplant the superior cervical ganglion (SCG), which contains norepinephrine and dopamine, into the brain. 1. Transplantation of SCG into rat cerebral cortex SCG was transplanted into the same rat's parietal cortex. Three weeks after the transplantation, catecholamine histofluorescence revealed many transplanted catecholamine cells in the cortex. However, no fibers extended from the transplanted tissue to the cerebral cortex. Some catecholamine fibers extended to the cerebral cortex where 6-OHDA (a specific neurotoxin to the catecholamine neuron) had been pretreated. 2. Transplantation of SCG into the caudate nucleus of MPTP-induced **Parkinson** monkey For animal model of **Parkinson** disease, MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine) was administered to 5 monkeys. Two weeks after MPTP administration, dopamine terminals disappeared in the caudate nucleus. After transplantation of SCG in the same animal, many transplanted SCG cells extended their axons to the caudate nucleus. The present results showed that transplanted SCG cells were well survived in the brain. Under a special circumstance such as shortage of catecholamine in the brain, transplanted SCG cells extended their axons into the brain. It is suggested that the transplantation of SCG can be a new therapy for **Parkinson** disease.

13/3,AB/13 (Item 1 from file: 5)  
DIALOG(R) File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

09640983 BIOSIS NO.: 199598095901

The role of excitatory amino acids in experimental models of **Parkinson's** disease.

AUTHOR: Ossowska K

AUTHOR ADDRESS: Dep. Neuro-Psychopharmacol., Inst. Pharmacol., Polish Acad. Sci., 12 Smetna St., PL-31-343 Krakow\*\*Poland

JOURNAL: Journal of Neural Transmission **Parkinson's** Disease and Dementia Section 8 (1-2):p39-71 1994

ISSN: 0936-3076

DOCUMENT TYPE: Literature Review

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: The aim of this article was to review the recent literature on the role of excitatory amino acids in **Parkinson's** disease and in animal equivalents of parkinsonian symptoms. Effects of NMDA and AMPA antagonists on the reserpine-induced akinesia, catalepsy and rigidity, on the neuroleptic-induced catalepsy, on the turning behaviour of 6-OHDA-lesioned rats, as well as on the parkinsonian symptoms evoked by MPTP in monkeys were analysed. Moreover, the role of NMDA antagonists in **Parkinson's**

disease was discussed. Data concerning the protective influence of these drugs on degenerative properties of methamphetamine, **MPTP** and 6-OHDOPA were also presented. On the basis of the above findings, the following conclusions may be drawn: (1) disturbances in the glutamatergic transmission in various brain structures seem to play a significant role in the development of symptoms of **Parkinson's** disease; (2) the NMDA-receptor blocking component may make a substantial contribution to the therapeutic effect of antiparkinsonian drugs; a similar contribution of AMPA-receptor blocking component has not been sufficiently documented, so far; (3) compounds blocking NMDA receptors may possibly prevent the development of **Parkinson's** disease; this presumption needs, however further studies; (4) side effects of NMDA receptor antagonists may be a limiting factor in the use of these compounds in humans.

1994

13/3,AB/14 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

08855802 BIOSIS NO.: 199396007303

Functional studies on monoaminergic transmitter release in

**Parkinsonism.**

AUTHOR: Wesemann Wolfgang(a); Grote Christoph; Clement Hans-Willi; Block Frank; Sontag Karl-Heinz

AUTHOR ADDRESS: (a)Dep. Neurochemistry, Inst. Physiological Chemistry, Philipps Univ., Hans-Meerwein-Strasse, D-355\*\*Germany

JOURNAL: Progress in Neuro-Psychopharmacology & Biological Psychiatry 17 (3):p487-499 1993

ISSN: 0278-5846

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: In vivo pulse voltammetry and apomorphine induced circling behaviour were used to study the effect of antiparkinsonian drugs and neurotoxins on striatal, extraneuronal dihydroxyphenylacetic acid (DOPAC) and 5-hydroxyindoleacetic acid (5-HIAA) concentrations which are a measure of dopamine (DA) release/DA metabolism and serotonin (5-HT) release, respectively. The DA precursor dihydroxyphenylalanine (DOPA, i.p.) increased extraneuronal DOPAC and reduced 5-HIAA levels whereas the opposite effect was induced by the 5-HT precursor 5-hydroxytryptophan (5-HTP, i.p.). Tryptophan, i.p., decreased the extraneuronal DOPAC levels without significant effect on 5-HT release. The monoamine oxidase (MAO) inhibitors pargyline, i.p., and deprenyl, i.p., as well as the DA agonist haloperidol, i.p., decreased the catechol signal. The DA antagonist haloperidol, i.p., increased extraneuronal DOPAC. In longterm studies unilateral application of the neurotoxins 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (**MPTP**), and 1-methyl-4-phenylpyridiniumcation (**MPP+**) into the substantia nigra pars compacta abolished the DOPAC signal in the striatum at the lesioned side. This effect can be partially or fully restored by DOPAC depending on the time elapsed after neurotoxin administration. In accordance with the voltammetric recorded unilateral lesion of the dopaminergic system the apomorphine stimulated circling behaviour was significantly enhanced in **MPTP** and **MPP+** treated rats as compared with controls. The results obtained indicate that antiparkinsonian drugs and neurotoxins besides their effect on total catecholamine and 5-HT concentrations change specifically the extraneuronal levels of the transmitter (metabolites). Moreover the results suggest that neurotoxin-treated rats can be used as a model to study **Parkinson**-like effects with regard to the pathogenesis and treatment of this disease.

1993

13/3,AB/15 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

08405418 BIOSIS NO.: 000094123072

NBQX 6 NITROSULFAMOYL BENZOQUINOXALINEDIONE AND CPP 3

CARBOXYPIPERAZINEPROPYLPHOSPHONIC ACID POTENTIATE DOPAMINE AGONIST

INDUCED ROTATIONS IN SUBSTANTIA NIGRA LESIONED RATS

AUTHOR: WACHTEL H; KUNOW M; LOESCHMANN P-A

AUTHOR ADDRESS: SCHERING AG, DEP. NEUROPSYCHOPHARMACOL., POSTFACH 65 03 11,  
D-1000 BERLIN 65, GERMANY.

JOURNAL: NEUROSCI LETT 142 (2). 1992. 179-182. 1992

FULL JOURNAL NAME: Neuroscience Letters

CODEN: NELED

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

ABSTRACT: Degeneration of dopaminergic nigrostriatal neurons in **primate models** of **Parkinson's** disease (PD) leads to an overactivity of excitatory glutamatergic projection from the subthalamic nucleus (STN) to the output nuclei of the basal ganglia resulting in rigidity and akinesia. The selective .alpha.-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) antagonist 6-nitro-sulfamoyl-benzo-quinoxaline-dione (NBQX) and the competitive N-methyl-D-aspartate (NMDA) antagonist 3-carboxy-piperazin-propyl phosphonic acid (CPP) ameliorate **parkinsonian** symptomatology when coadministered with threshold doses of L-DOPA in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (**MPTP**)-treated common marmosets and **induce** rotations in rats with unilateral 6-hydroxydopamine (6-**OHDA**) lesions of the substantia nigra (SN). Here we report that in the 6-**OHDA**-lesioned rat NBQX and CPP **induce** contralateral rotations when combined with threshold doses of the direct dopamine agonists lisuride or apomorphine. AMPA antagonists and competitive NMDA antagonists may therefore be suitable as adjuvants for the treatment of PD.

1992

? ds

Set	Items	Description
S1	7575	PARKINS? AND MODEL?
S2	0	S1 AND ANIMAL?
S3	6564	S1 AND ANIMAL?
S4	9	S3 AND GAD? AND PY<1999
S5	6	RD (unique items)
S6	4046	S3 AND PY<1999
S7	2028	S6 AND (PRIMATE OR MOUSE OR MURINE OR RAT OR RODENT)
S8	992	S7 AND INDUC?
S9	150	S8 AND OHDA
S10	286	S8 AND MPTP
S11	23	S9 AND S10
S12	15	RD (unique items)
S13	15	S12 NOT S5



s parkins? and model?  
         67069 PARKINS?  
         1593189 MODEL?  
       S1      7575 PARKINS? AND MODEL?  
 ? s s1 and annimal?  
         7575 S1  
           6 ANNIMAL?  
       S2      0 S1 AND ANNIMAL?  
 ? s s1 and animal?  
 Processing  
         7575 S1  
         13784474 ANIMAL?  
       S3      6564 S1 AND ANIMAL?  
 ? s s3 and gad? and py<1999  
 Processing  
         6564 S3  
         29890 GAD?  
         21929126 PY<1999  
       S4      9 S3 AND GAD? AND PY<1999  
 ? rd  
 ...completed examining records  
       S5      6 RD (unique items)  
 ? t s5/3,ab/all

5/3,AB/1 (Item 1 from file: 155)  
 DIALOG(R)File 155:MEDLINE(R)

09781969 98197141 PMID: 9527896

Toxicity of dieldrin for dopaminergic neurons in mesencephalic cultures.  
 Sanchez-Ramos J; Facca A; Basit A; Song S  
 Department of Neurology, University of South Florida, James A. Haley VA  
 Medical Center, Research 151, 13000 Bruce B Downs Boulevard, Tampa, Florida  
 33612, USA.

Experimental neurology (UNITED STATES) Apr 1998, 150 (2)  
 p263-71, ISSN 0014-4886 Journal Code: 0370712  
 Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Dieldrin can be retained for decades in lipid-rich tissue and has been measured in some postmortem PD brains. Dieldrin has been reported to deplete brain monoamines in several species and has been shown to inhibit mitochondrial respiration. To further investigate the possibility that it may be involved in the pathogenesis of **parkinsonism**, its toxicity for dopaminergic (DA) neurons was assessed in a mesencephalic cell culture **model**. Primary neuronal cultures of mesencephalic neurons were prepared from fetal rats or fetal mice, grown for 1 week and incubated with Dieldrin (0.01-100 microm) for 24 or 48 h. Toxicity for DA neurons was determined by measuring density of surviving tyrosine hydroxylase immunoreactive (TH-ir) cells. Toxicity for gamma-aminobutyric acid (GABA)-ergic neurons was determined by measuring survival of glutamate decarboxylase (**GAD**)-ir neurons. General, nonselective cytotoxicity was determined by counting cells visualized by phase contrast microscopy or by DAPI-stained cells with fluorescence microscopy. Dieldrin exposure for 24 h resulted in a dose-dependent decrease in survival of TH-IR cells (DA neurons) with a 50% decrease (EC50) produced by 12 microm in rat mesencephalic cultures. Dieldrin also produced a dose- and time-dependent decrease in mouse DA-ergic and GABA-ergic neurons in mouse mesencephalic cultures. GABA-ergic neurons were less sensitive to the toxin compared to DA-ergic neurons. Cellular uptake of 3H-DA was also affected by lower concentrations of Dieldrin (EC50 = 7.98 microm) than uptake of 3H-GABA (EC50 = 43 microm). Thus, Dieldrin appears to be a relatively selective DA-ergic neurotoxin in mesencephalic cultures. Dieldrin, which may be ubiquitous in the environment, is proposed as an agent which can initiate

and promote dopaminergic neurodegeneration in susceptible individuals.  
Copyright 1998 Academic Press.

5/3,AB/2 (Item 2 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)

09519041 97410058 PMID: 9266773

Glutamate decarboxylase (**GAD67** and **GAD65**) gene expression is increased in a subpopulation of neurons in the putamen of **Parkinsonian** monkeys.

Soghomonian J J; Laprade N

Centre de Recherche en Neurobiologie et Departement d'Anatomie, Faculte de Medecine, Universite Laval, Quebec, Canada. Jean-Jacques.Soghomonian@anm.ulaval.ca

Synapse (New York, N.Y.) (UNITED STATES) Oct 1997, 27 (2)

p122-32, ISSN 0887-4476 Journal Code: 8806914

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

The cellular distribution of the mRNAs encoding for the two isoforms of glutamate decarboxylase, **GAD67** and **GAD65**, was analyzed by in situ hybridization histochemistry in the caudate nucleus and putamen of control and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated **parkinsonian** squirrel monkeys. On brain sections processed with a radioactive and a digoxigenin-labeled cRNA probe, the **GAD67** and **GAD65** mRNAs were colocalized in virtually all labeled neurons of the caudate nucleus and putamen, in both control and MPTP-treated monkeys. Furthermore, neurons labeled with the **GAD** cRNAs constituted at least 90% of all striatal neurons, as estimated on adjacent Nissl-stained sections. In the two groups of monkeys, double-labeling experiments using a combination of radioactive **GAD67** or **GAD65** and digoxigenin-labeled preproenkephalin (PPE) cRNA probes showed that roughly half of all neurons labeled with the **GAD** cRNAs were also labeled with the PPE cRNA probe. When compared to controls, **GAD67** and **GAD65** mRNA levels were higher in the putamen, and to a lesser extent in the caudate nucleus, of MPTP-treated monkeys. Further analysis of labeling at the cellular level in a dorsolateral sector of the putamen revealed that **GAD67** and **GAD65** mRNA levels in MPTP-treated monkeys were increased in PPE-labeled (presumed striato-pallidal) neurons but not in PPE-unlabeled (presumed striato-nigral) neurons. Our results demonstrate that most neurons in the caudate nucleus and putamen of squirrel monkeys contain the mRNAs encoding for the two **GAD** isoforms. In addition, the selective increase in **GAD** mRNA levels in PPE-labeled neurons provides further evidence that striato-pallidal GABAergic neurons are hyperactive in MPTP-treated **parkinsonian** monkeys.

5/3,AB/3 (Item 3 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)

07616026 93137245 PMID: 8093682

An **animal model** for coexisting tardive dyskinesia and tardive **parkinsonism**: a glutamate hypothesis for tardive dyskinesia.

Gunne L M; Andren P E

Department of Psychiatry, Ulleraker, Uppsala University, Sweden.

Clinical neuropharmacology (UNITED STATES) Feb 1993, 16 (1)

p90-5, ISSN 0362-5664 Journal Code: 7607910

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

There is now ample evidence for long-term malfunctioning within five

different brain GABAergic pathways in a monkey model for tardive dyskinesia (TD). Three of these GABA connections (GPe-STN, CP-SNr, and CP-GPi) are chronically downregulated during neuroleptic treatment and after some years they do not seem to regain their normal activity, even when the neuroleptics are discontinued. The persistent downregulation of these three GABA connections, evidenced by depressions of terminal GAD activity and GABA levels, appears to be a conceivable mechanism behind tardive parkinsonism (TP), often reported to coexist with TD in the clinic. The TD patients' well-known lack of awareness of their symptoms may be due to their parkinsonian "sensory neglect." Another two GABA malfunctioning connections were found in our monkey model: SNr-VA/VL and GPi-VA/VL. These pathways are upregulated during chronic neuroleptic treatment, partly due to an elevated glutamate release within subthalamofugal pathways. This chronic glutamatergic hyperactivity may have acted via an excitotoxic mechanism and consequently both GPi and VA/VL had a low synaptic activity in our dyskinetic monkeys, as measured by 2-deoxyglucose uptake, even 4 months after the last neuroleptic dose. It is hypothesized that TD may be due to an excitotoxic lesion of the inhibitory GABAergic VA/VL afferents, while TP has to do with persistent malfunctioning of downregulated SNr and GPi afferents.

5/3,AB/4 (Item 4 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)

04178304 83163228 PMID: 6131932

Striatal GABAergic neuronal activity is not reduced in Parkinson's disease.

Perry T L; Javoy-Agid F; Agid Y; Fibiger H C

Journal of neurochemistry (UNITED STATES) Apr 1983, 40 (4)

pl120-3, ISSN 0022-3042 Journal Code: 2985190R

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

The content of gamma-aminobutyric acid (GABA) and the activities of glutamic acid decarboxylase (GAD) and tyrosine hydroxylase (TH) were measured in whole putamen obtained at autopsy from 13 patients dying with idiopathic Parkinson's disease and 13 appropriate control subjects. Mean GABA content was significantly elevated (by 28%) in the putamen of the Parkinson's disease patients. TH activity was markedly reduced, while there was no significant reduction of GAD activity in the putamen of these patients. GABA content was also measured in both sides of the striatum in rats which had received unilateral injections of 6-hydroxydopamine (6-OHDA) in the vicinity of the axons of the nigrostriatal projection. Mean GABA content was found significantly elevated (by 33%) in the ipsilateral striatum. Loss of dopaminergic nigrostriatal neurons, in both human Parkinson's disease and in the rat 6-OHDA model, is accompanied by increased striatal GABA content. The assumption that GABAergic neurotransmission is reduced in the striatum in Parkinson's disease may not be correct.

5/3,AB/5 (Item 1 from file: 5)  
DIALOG(R) File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

11732615 BIOSIS NO.: 199800514346

Novel synthesis and release of GABA in cerebellar granule cell cultures after infection with defective herpes simplex virus vectors expressing glutamic acid decarboxylase.

AUTHOR: New Kent C; Gale Karen; Martuza Robert L; Rabkin Samuel D(a)

AUTHOR ADDRESS: (a)Dep. Microbiol., Georgetown Univ. Medical Cent., 3970 Reservoir Road NW, Washington, DC 20007\*\*USA

JOURNAL: Molecular Brain Research 61 (1-2):p121-135 Oct. 30, 1998  
ISSN: 0169-328X  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

**ABSTRACT:** The inhibitory amino acid neurotransmitter gamma-aminobutyric acid (GABA) is synthesized from glutamate in a single step by the enzyme glutamic acid decarboxylase (GAD). We sought to determine whether viral vectors containing GAD cDNA could be used to enhance synthesis and stimulation-evoked release of GABA in cultures of CNS neurons. For this purpose, we generated double-cassette defective herpes simplex virus (HSV) vectors that expressed one of the two GAD isoforms (GAD65 or GAD67), and Escherichia coli LacZ. Infection of cerebellar granule cell (CGC) cultures with vectors containing GAD cDNA resulted in a significant increase in isoform-specific expression of GAD, synthesis of GABA, and stimulation-evoked GABA release. GAD65 and GAD67 vector-infected neurons exhibited a comparable profile of GABA levels, synthesis and release, as well as GAD protein distribution. In CGCs cultured for 6 days in vitro (DIV), GABA synthesized after vector-derived GAD expression was released by treatment with glutamate or veratridine, but only in a Ca<sup>2+</sup>-independent fashion. In more mature (10 DIV) cultures, both Ca<sup>2+</sup>-dependent, K<sup>+</sup> depolarization-induced, as well as Ca<sup>2+</sup>-independent, veratridine-induced, GABA release was significantly enhanced by GAD vector infection. Treatment of CGCs with kainic acid, which destroys most of the GABAergic neurons (< 1% remaining), did not prevent vector-derived expression of GAD nor synthesis of GABA. This suggests that defective HSV vector-derived GAD expression can be used to increase GABA synthesis and release in CNS tissue, even in the relative absence of GABAergic neurons. The use of such GAD vectors in the CNS has potential therapeutic value in neurologic disorders such as epilepsy, chronic pain, Parkinson's and Huntington's disease.

1998

5/3,AB/6 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

03965451 BIOSIS NO.: 000076051017  
STRIATAL GAMMA AMINO BUTYRIC-ACID-ERGIC NEURONAL ACTIVITY IS NOT REDUCED IN  
**PARKINSON DISEASE**  
AUTHOR: PERRY T L; JAVOY-AGID F; AGID Y; FIBIGER H C  
AUTHOR ADDRESS: DEP. PHARMACOL., UNIV. BRITISH COLUMBIA, VANCOUVER V6T 1W5,  
CANADA.  
JOURNAL: J NEUROCHEM 40 (4). 1983. 1120-1123. 1983  
FULL JOURNAL NAME: Journal of Neurochemistry  
CODEN: JONRA  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

**ABSTRACT:** The content of GABA and the activities of glutamic acid decarboxylase (GAD) and tyrosine hydroxylase (TH) were measured in whole putamen obtained at autopsy from 13 patients dying with idiopathic Parkinson's disease and 13 appropriate control subjects. Mean GABA content was significantly elevated (by 28%) in the putamen of the Parkinson's disease patients. TH activity was markedly reduced, while there was no significant reduction of GAD activity in the putamen of these patients. GABA content was also measured in both sides of the striatum in rats which had received unilateral injections of 6-hydroxydopamine (6-OHDA) in the vicinity of the axons of the nigrostriatal projection. Mean GABA content was found significantly

elevated (by 33%) in the ipsilateral striatum. Loss of dopaminergic nigrostriatal neurons, in both human **Parkinson's** disease and in the rat 6-OHDA model, is accompanied by increased striatal GABA content. The assumption that GABAergic neurotransmission is reduced in the striatum in **Parkinson's** disease may not be correct.

1983

? ds

Set	Items	Description
S1	7575	PARKINS? AND MODEL?
S2	0	S1 AND ANNIMAL?
S3	6564	S1 AND ANIMAL?
S4	9	S3 AND GAD? AND PY<1999
S5	6	RD (unique items)
? s s3 and py<1999		
	6564	S3
	21929126	PY<1999
S6	4046	S3 AND PY<1999
? s s6 and (primate or mouse or murine or rat or rodent)		
	4046	S6
	35874	PRIMATE
	843487	MOUSE
	225668	MURINE
	1703963	RAT
	52620	RODENT
S7	2028	S6 AND (PRIMATE OR MOUSE OR MURINE OR RAT OR RODENT)
? s s7 and induc?		
	2028	S7
	2528050	INDUC?
S8	992	S7 AND INDUC?
? rd		
...examined 50 records (50)		
...examined 50 records (100)		
...examined 50 records (150)		
...examined 50 records (200)		
<-----User Break----->		
u!		
>>>Duplicate detection halted.		

?

PLEASE ENTER A COMMAND OR BE LOGGED OFF IN 5 MINUTES

? s s8 and

>>>Possible typing error near end of command

? ds

Set	Items	Description
S1	7575	PARKINS? AND MODEL?
S2	0	S1 AND ANNIMAL?
S3	6564	S1 AND ANIMAL?
S4	9	S3 AND GAD? AND PY<1999
S5	6	RD (unique items)
S6	4046	S3 AND PY<1999
S7	2028	S6 AND (PRIMATE OR MOUSE OR MURINE OR RAT OR RODENT)
S8	992	S7 AND INDUC?
? s s8 and ohda		
	992	S8
	6007	OHDA
S9	150	S8 AND OHDA
? s s8 and mptp		
	992	S8
	5685	MPTP
S10	286	S8 AND MPTP
? s s9 and s10		